Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis

Rheumatology

Volumn 50, Issue SUPPL. 4, 2011, Pages

  Bojke, Laura ^a   Epstein, David ^a   Craig, Dawn ^b   Rodgers, Mark ^b   Woolacott, Nerys ^b   Yang, Huiqin ^b   Sculpher, Mark ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Biologics; Cost effectiveness; Decision model; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB;

ARTICLE; BIOLOGICAL THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; HUMAN; PALLIATIVE THERAPY; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; PSORIATIC ARTHRITIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STATISTICAL MODEL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052222351     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker245     Document Type: Article

References (61)

1. Gladman DD, Antoni C, Mease P, Clegg D, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl. II):ii14-7.
2. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7.
3. Williams JP, Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care 2002;8:S664-81.
4. The NHS Information Centre. Hospital Prescribing, 2008: England. http://www.ic.nhs.uk/, 2009 (last accessed 13 November 2009).
5. Armstrong D, McCausland E, Wright G. The impact of anti-TNF-alpha therapy on the nature of service provision. Rheumatology 2006;45:112.
6. Woolacott N, Bravo Vergel Y, Hawkins N et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006;10:1-239.
7. Rodgers M, Epstein D, Bojke L et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. London: National Institute for Clinical Excellence, 2009.
8. McHugh N. BSR guideline for anti-TNFa therapy in psoriatic arthritis. London: British Society for Rheumatology, 2004.
9. Smith CH, Anstey AV, Barker JNWN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Brit J Dermatol 2005;153:486-97.
10. National Institute for Health and Clinical Excellence (NICE). Updated guide to the methods of technology appraisal. London: NICE, 2008.
11. Kyle S, Chandler D, Griffiths CE et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis [erratum appears in Rheumatology (Oxford) 2005;44:569]. Rheumatology 2005;44:390-7.
12. O'Hagan A, Buck CE, Daneshkhah A et al. Uncertain judgements: eliciting experts' probabilities. Chichester: Wiley, 2006.
13. Wong K, Gladman DD, Husted J et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. 1. Causes and risk of death. Arthritis Rheum 1997;40: 1868-72.
14. Sutton A, Ades AE, Cooper N, Abrams Kl. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008;26:753-67.
15. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356: 385-90.
16. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
17. Mease PJ, Kivitz AJ, Burch FX et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21.
18. Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept inelderly subjects with rheumatic diseases. Ann Rheum Dis 2006;65:379-84.
19. Lebwohl M, Tyring SK, Hamilton TK et al. Etanercept in psoriatic arthritis: sustained improvement in skin and joint disease and inhibition of radiographic progression at years [abstract 155-09]. J Am Acad Dermatol 2005; 52(Suppl. 2):AB8.
20. Wanke LA, Mease PJ, Gottlieb AB. Sustained improvement in functional status and vitality of psoriatic arthritis patients treated with etanercept [abstract 382]. J Investigat Dermatol 2004;122:A64.
21. Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF. Patient-reported outcomes in a randomized comparison of etanercept and placebo for treatment of psoriatic arthritis [abstract SAT0279]. Ann Rheum Dis 2006;65(Suppl. 2):535.
22. Centocor. A multicenter placebo-controlled, double-blind, randomised study of anti-TNF chimeric monoclonal antibody (cA2, infliximab) in patients with active psoriatic arthritis (IMPACT): protocol no. P02114 [industry submission]. Malvern, PA: Centocor, 2003.
23. Schering-Plough Ltd. Remicade in the treatment of psoriatic arthritis in the United Kingdom: a submission to the National Institute for Clinical Excellence [industry submission]. Kenilworth, NJ: Schering-Plough Ltd, 2004.
24. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52: 1227-36.
25. Antoni CE, Kavanaugh A, van der Heijde D et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheum 2008;35:869-76.
26. Kavanaugh A, Antoni CE, Gladman D et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006;65:1038-43.
27. Kavanaugh A, Krueger GG, Birbara C et al. Treatment with infliximab is associated with "major clinical response" in psoriatic arthritis patients treated with infliximab: analysis of two double-blind placebo controlled trials [abstract OP0104]. Ann Rheum Dis 2006; 65(Suppl. 2):85.
28. Kavanaugh A, Krueger GG, Birbara C et al. Treatment with infliximab is associated with "major clinical response" in psoriatic arthritis patients treated with infliximab: analysis of two double-blind placebocontrolled trials [abstract 121]. J Investigat Dermatol 2007;127:1824.
29. Antoni CE, Kavanaugh A, Kirkham B et al. 2-year data: infliximab maintains clinical response in psoriatic arthritis patients-data from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [abstract 485]. Arthritis Rheum 2005;52(Suppl. S(9)):S209.
30. Antoni CE, Kavanaugh A, Kirkham B et al. Two-year data: infliximab maintains clinical response in psoriatic arthritis patients - an analysis of the year 2 data from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [abstract OP0080]. Ann Rheum Dis 2005; 64(Suppl. 3):82.
31. Antoni CE, Kavanaugh A, Gladman D et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year [abstract OP0156]. Ann Rheum Dis 2005;64(Suppl. 3):107.
32. Antoni CE, Kavanaugh A, Kirkham B et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy [abstract OP0082]. Ann Rheum Dis 2003;62(Suppl. 1):90.
33. Antoni CE, Kavanaugh A, Kirkham B et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT1): the concomitant use of DMARDs does not influence the efficacy and safety of infliximab over a one year period [abstract SAT0083]. Ann Rheum Dis 2004;63(Suppl. 1): 411-2.
34. Antoni C, Krueger G, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64: 1150-7.
35. van der Heijde D, Kavanaugh A, Gladman DD et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007;56: 2698-707.
36. Kavanaugh A, Krueger GG, Beutler A et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007;66: 498-505.
37. Kavanaugh A, Antoni CE, Mease P et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006;33:2254-9.
38. Kavanaugh A, Antoni CE, Krueger GG et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006;65: 471-7.
39. Papp K, Menter A, Antoni C et al. Rapid and persistent improvement of psoriasis in patients with active psoriatic arthritis treated with infliximab: 24-week results of the impact 2 trial [abstract P028]. J Eur Acad Dermatol Venereol 2004;18:783.
40. Kavanaugh A, Krueger GG, Birbara C et al. Treatment with infliximab is associated with "major clinical response" in psoriatic arthritis patients treated with infliximab: analysis of two double-blind placebo controlled trials [abstract L18]. Arthritis Rheum 2005;52:4065.
41. Kavanauagh A, Krueger GG, de Vlam K et al. Infliximab significantly improves joint and skin involvement in psoriatic arthritis to a substantial extent and irrespective of baseline joint involvement or MTX use: analysis of clinical response from the IMPACT2 trial [abstract 1637]. Arthritis Rheum 2004;50(Suppl. S (9)):S617.
42. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
43. Mease PJ, Ory P, Sharp JT et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
44. Gladman DD, Mease PJ, Ritchlin CT et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88.
45. Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007;66:163-8.
46. Choy E, Gladman D, Sasso E. Efficacy of adalimumab by disease duration in psoriatic arthritis: subanalysis of ADEPT [abstract P2748]. J Am Acad Dermatol 2007; 56(Suppl. 2):AB186.
47. Gladman D, Mease P, Ritchlin C, Okun M. PASI-100 is associated with better dermatology-specific patient-reported outcomes compared with PASI-75e99 in adalimumab-treated patients with psoriatic arthritis: subanalysis of ADEPT [abstract P2746]. J Am Acad Dermatol 2007;56(Suppl. 2):AB185.
48. Gladman D, Mease P, Kavanaugh A, Weinberg M. Adalimumab is efficacious in treating skin disease in psoriatic arthritis: subanalysis of moderate versus severe psoriasis in the ADEPT trial [abstract P40]. J Am Acad Dermatol 2006;54(Suppl. 1):AB10-11.
49. Mease P, Gladman DD, Ritchlin CT et al. Clinical efficacy, safety and inhibition of joint destruction of adalimumab in the treatment of moderate to severe psoriatic arthritis: 48-week results of the ADEPT trial [abstract P2865]. J Am Acad Dermatol 2006; 54(Suppl. 1):AB214.
50. Mease P, Sharp JT, Ory P et al. Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: results from ADEPT [abstract P06.12]. J Eur Acad Dermatol Venereol 2005; 19(Suppl. 2):163.
51. Genovese MC, Mease PJ, Thomson GTD et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifyingantirheumatic drug therapy. J Rheumatol 2007;34: 1040-50.
52. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37.
53. British National Formulary 58. London: British Medical Association, 2009.
54. Kobelt G, Jö nsson L, Lindgren P, Young A, Eberhardt K. Modelling the progression of rheumatoid arthritis:a two-country model to estimate costs to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002;46:2310-9.
55. Kobelt G, Jö nsson L, Young A, Eberhardt K. The cost effectiveness of infliximab in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42: 326-35.
56. Department of Health. Reference costs 2007-2008. London: NHS.
57. Poyner T, Wall A, Adnitt PAM. Economic impact of psoriasis treatment on the patient and on the National Health Service. J Dermatol Treatment 1999;10:25-9.
58. Hartman M, Prins M, Swinkels OQ et al. Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment. Brit J Dermatol 2003;147:538-44.
59. Johannesson M, Weinstein S. On the decision rules of cost-effectiveness analysis. J Health Econ 1993;12: 459-67.
60. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis. a literature review from a global health systems perspective. Pharm Therapeut 2010;35: 680-9.
61. Yang H, Epstein D, Bojke L et al. Evidence Review Group's Report: golimumab for the treatment of psoriatic arthritis. London: National Institute for Health and Clinical Excellence, 2010.